Best Momentum Stocks to Buy for October 14th Zacks Investment Research - Mon Oct 14, 2024 Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 14th:IAMGOLD Corporation IAG: This intermediate gold producer has a Zacks Rank #1 and witnessed...
New Strong Buy Stocks for October 14th Zacks Investment Research - Mon Oct 14, 2024 Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:HireQuest, Inc. HQI: This company that provides temporary staffing solutions has seen the Zacks Consensus Estimate for its current...
Three (3) Stocks Under $10 That Insiders Are Buying MarketBeat - Wed Jul 5, 2023 These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI.
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023 Business Wire - Mon May 8, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer Business Wire - Tue Apr 11, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David...
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results Business Wire - Tue Mar 28, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023 Business Wire - Mon Mar 20, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Mon Mar 13, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors Business Wire - Mon Mar 6, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results Business Wire - Wed Nov 9, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022 Business Wire - Mon Nov 7, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference Business Wire - Mon Oct 31, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial Business Wire - Wed Oct 26, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company...
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations Business Wire - Wed Sep 14, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...
DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference Business Wire - Tue Sep 6, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results Business Wire - Wed Aug 10, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022 Business Wire - Thu Aug 4, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second...
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022 Business Wire - Mon Aug 1, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s...
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199 Business Wire - Wed Jul 6, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S....
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors PR Newswire - Fri Jun 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders...
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022 Business Wire - Wed May 25, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will...
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results Business Wire - Wed May 4, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022 Business Wire - Thu Apr 28, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first...
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results Business Wire - Mon Mar 14, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer Business Wire - Wed Feb 2, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...
DiaMedica Therapeutics to Present Research at International Stroke Conference Business Wire - Tue Jan 25, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company...
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer Business Wire - Wed Jan 5, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event Business Wire - Mon Dec 13, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company...
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference Business Wire - Wed Nov 17, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results Business Wire - Wed Nov 10, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021 Business Wire - Tue Nov 9, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will...
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial Business Wire - Mon Nov 8, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S....
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021 Business Wire - Thu Nov 4, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its third...
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021 Business Wire - Mon Oct 18, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking...
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke Business Wire - Thu Sep 30, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S....
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement Business Wire - Tue Sep 28, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing...
DiaMedica Therapeutics Announces $30 Million Private Placement Business Wire - Mon Sep 27, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered...
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke Business Wire - Mon Sep 13, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation...
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences Business Wire - Tue Sep 7, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company...
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results Business Wire - Wed Aug 11, 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...
HireQuest Reports Financial Results for the Fourth Quarter and Year End 2021 ACCESS Newswire - Tue Mar 15, 2022 Q4 2021 EPS of $0.16 per Diluted Share, Net Income of $2.2 million, and Adjusted EBITDA of $3.5 million Full Year 2021 EPS of $0.87 per Diluted Share, Net Income of $11.8 million, and Adjusted EBITDA of...
HireQuest, Inc. To Hold Fourth Quarter and Year End 2021 Financial Results Conference Call on Tuesday, March 15, 2022 ACCESS Newswire - Mon Mar 7, 2022 GOOSE CREEK, SC / ACCESSWIRE / March 7, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, commercial, and professional staffing services, today announced that it will...
HireQuest, Inc. Announces Closing of Northbound Executive Search Acquisition ACCESS Newswire - Mon Feb 28, 2022 GOOSE CREEK, SC / ACCESSWIRE / February 28, 2022 / HireQuest, Inc. (Nasdaq:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the...
HireQuest, Inc. Announces Closing of The Dubin Group and Dubin Workforce Solutions Acquisition ACCESS Newswire - Tue Feb 22, 2022 GOOSE CREEK, SC / ACCESSWIRE / February 22, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the...
HireQuest, Inc. Declares Quarterly Dividend ACCESS Newswire - Tue Feb 22, 2022 GOOSE CREEK, SC / ACCESSWIRE / February 22, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that its Board of Directors...
HireQuest, Inc. Announces Acquisition of Northbound Executive Search ACCESS Newswire - Tue Jan 25, 2022 HireQuest to Acquire Executive Placement and Short-term Consultant Firm in New York GOOSE CREEK, SC / ACCESSWIRE / January 25, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary,...
HireQuest, Inc. Announces Closing of dmDickason Acquisition ACCESS Newswire - Mon Jan 24, 2022 GOOSE CREEK, SC / ACCESSWIRE / January 24, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the...
HireQuest, Inc. Announces Acquisition of The Dubin Group, Inc. and Dubin Workforce Solutions, Inc. ACCESS Newswire - Wed Jan 19, 2022 HireQuest to Acquire Commercial Staffing and Executive Placement Providers in Philadelphia GOOSE CREEK, SC / ACCESSWIRE / January 19, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand,...
HireQuest, Inc. Announces Acquisition of dmDickason’s Staffing Division Business Wire - Mon Jan 10, 2022 HireQuest, Inc. (Nasdaq: HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has entered into a definitive agreement to acquire the staffing division...
HireQuest, Inc. Announces Closing of Dental Power Staffing Acquisition Business Wire - Tue Dec 7, 2021 HireQuest, Inc. (Nasdaq: HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the previously disclosed acquisition of the Dental...